Welcome to our dedicated page for TNF Pharmaceuticals news (Ticker: TNFA), a resource for investors and traders seeking the latest updates and insights on TNF Pharmaceuticals stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect TNF Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of TNF Pharmaceuticals's position in the market.
TNF Pharmaceuticals (NASDAQ: TNFA) has partnered with Renova Health to study isomyosamine (MYMD-1) as a treatment for GLP-1-induced sarcopenia and frailty. The fully funded trial will evaluate TNF-α levels in patients using Wegovy or Ozempic who show inflammation associated with sarcopenia.
Studies indicate up to 40% of GLP-1-related weight loss comes from lean body mass, including muscle. If successful, isomyosamine could become a first-in-class therapy for preserving muscle mass during GLP-1 weight loss. The GLP-1 market is valued at $49.3 billion in 2024 and projected to reach $105 billion by 2029.
TNFA is currently conducting a Phase 2 trial for aging-related sarcopenia and plans to launch a Phase 2b study in Q1 2025 following positive Phase 2a results.
TNF Pharmaceuticals (NASDAQ: TNFA) announced significant positive topline results from a Phase 2a study of MYMD-1® (isomyosamine) for sarcopenia treatment. The double-blind, placebo-controlled study in patients aged 65+ showed significant decreases in inflammatory biomarkers, including TNF-α (P=0.008), IL-6 (P=0.03), and sTNFR1 (P=0.02), with no serious adverse events reported.
Based on these results, the company plans to initiate a Phase 2b study in early 2025. The global TNF inhibitor market is valued at $39.7 billion in 2024, expected to reach $47.3 billion by 2029. The sarcopenia treatment market, currently at $3.07 billion, is projected to grow to $4.02 billion by 2029, with over 50 million people affected globally.
TNF Pharmaceuticals (Nasdaq: TNFA) is advancing its lead program, MYMD-1®, through fully funded mid-stage clinical trials. MYMD-1 is a small molecule that blocks excessive TNF-alpha activity to regulate the immuno-metabolic system. The company's next clinical studies will focus on sarcopenia/frailty following statistically significant results from a Phase 2 study.
MYMD-1 met primary endpoints in reducing chronic inflammatory markers with statistical significance in sarcopenia/frailty. The company also holds FDA-cleared Phase 2 INDs for MYMD-1 in rheumatoid arthritis and Hashimoto's thyroiditis. TNFA is preparing to reveal its next steps towards value creation and long-term growth.
TNF Pharmaceuticals, formerly MyMD Pharmaceuticals, has begun trading under its new Nasdaq stock symbol TNFA as of July 24, 2024. This change reflects the company's focus on inhibiting TNF-alpha to regulate the immuno-metabolic system. The company's lead clinical candidate, MYMD-1, blocks excess TNF-α activity, potentially restoring immune system control and regulation.
Dr. Mitchell Glass, President and Chief Medical Officer, emphasized that this rebranding aligns with their core science and highlights MYMD-1's potential as the first TNF-α inhibitor in its indication. The company's CUSIP remains unchanged, and current stockholders need not take any action regarding the symbol change.
FAQ
What is the current stock price of TNF Pharmaceuticals (TNFA)?
What is the market cap of TNF Pharmaceuticals (TNFA)?
